Skip to contentM
Marker Therapeutics, Inc.
M
MRKRMarker Therapeutics, Inc. Q2 2026 · 10-Q
Revenue—
Net Income-$1.83M-$1.83MN/M vs Q2 2025 EPS Diluted-$0.09-$0.09N/M vs Q2 2025 Operating Income-$2,620,366N/M Operating Cash Flowderived-$3,716,323N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end